secwatch.observer — SEC 8-K summary
======================================

Issuer:     Design Therapeutics, Inc. (DSGN)
CIK:        0001807120
Form:       8-K
Filed at:   2026-04-28T23:59:59+00:00
Accession:  0001193125-26-187012
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Design Therapeutics Q1 net loss $17.6M; cash $222.8M funds ops into 2029; pipeline on track
--------------------------------------------------------------------------------

- Net loss of $17.6M for Q1 2026; R&D expense $14.4M, G&A $5.3M.
- Cash, equivalents and securities total $222.8M as of March 31, 2026, providing runway to 2029.
- DT-216P2 Phase 1/2 RESTORE-FA trial dosing continues; frataxin update expected H2 2026.
- DT-168 Phase 2 FECD trial ongoing with data in H2 2026; DT-818 DM1 Phase 1 MAD trial to begin dosing H1 2026.
- David Shapiro, M.D., appointed to board of directors in March 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1807120/000119312526187012/0001193125-26-187012-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1807120/000119312526187012/dsgn-20260428.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-187012

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer